Catherine Warne made chief executive at Red Door
pharmafile | April 6, 2010 | Appointment | Medical Communications | Creston, Red Door, appointment, medical communications
Red Door has made Catherine Warne chief executive as part of a reorganisation that also sees promotions for Catherine Oliver, Nicola Walsby, Joanne Neave and Paul Turnbull.
Catherine Warne co-founded Red Door Communications (RDC) ten years ago and it has since become of the largest healthcare PR consultancies in the UK.
In her new role she will oversee both businesses as well as explore new offerings, either as start-ups or acquisitions.
In addition, as joint head of the health division within Creston plc, she will be working to further develop the group offering of best-in class companies who provide services across PR, medical education, digital, market research and consumer health.
“We believe that there are other opportunities out there for our group to diversify and adapt to the evolving and dynamic market place,” Catherine said. “My new role is to help us to realise these opportunities.”
Day-to-day running of the consultancy will be taken over by Catherine Oliver, who becomes managing director of RDC.
She has worked for 13 years with founders Catherine Warne and Julia Harries, the latter of whom returns from maternity leave in May as client strategy director.
The agency has also promoted Nicola Walsby to the Board and a position as director of RDC.
Meanwhile in recognition of growth at its medical education arm ROCK, Joanne Neave (neé Satchell) has been promoted to the newly-created position of director of ROCK Medical Communications, reporting to Catherine Warne.
Finally, finance director Paul Turnbull has been promoted to another new position -divisional finance director for the Creston Health group of companies, where he will look after RDC, ROCK Medical Communications and PAN Advertising.
Related Content
Men’s health – a new report from the Department of Health and Social Care
The UK Department of Health and Social Care has published a new report entitled Men’s …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
